iData’s global syringe and needle market MedCore covers both the needle market and the syringe market. Medcores include a highly detailed and in-depth look at a segment in a market with all the associated sub- and sub-sub segments. iData MedCore reports allow users to delve deep into a specific market in order to obtain units sold, average selling prices (ASPs), market values, growth rates, a 10-year forecast including historical and future market estimates, and competitor market shares of any given market segment.

Throughout this medical market research on the U.S. and European diabetes monitoring, treatment, and drug delivery markets, over 90 companies across 16 countries were analyzed. To conduct this research, our comprehensive methodology was utilized to understand the market sizes, unit sales, company market shares, and to create accurate forecasts. Previously, the U.S. diabetes monitoring, treatment, and

The U.S. and European insulin markets include long-acting insulin, ultra-long-acting insulin, rapid-acting insulin, premixed insulin, and human insulin. Within both the U.S. and the European markets the largest segment was the long-acting insulin market, which accounted for over 37% of the total market value. The long-acting insulin market has experienced increased competition, due to the expiration

The U.S. and European insulin pump markets include durable pumps and patch pumps, which are further segmented to account for hardware and disposable components. Within both the U.S. and the European insulin pump markets, the largest segment was the durable pump market, which accounted for the majority of the total market value. Durable pumps account for

The European diabetes monitoring, treatment, and drug delivery market, also referred to as the diabetes care market, includes blood glucose meters, blood glucose test strips, lancets, continuous glucose monitoring (CGM), flash glucose monitoring (FGM), insulin, insulin pens, insulin syringes, and insulin pumps. Previously, the European diabetes monitoring, treatment, and drug-delivery market was valued at €6.8 billion.

The U.S. diabetes monitoring, treatment, and drug delivery market, also referred to as the diabetes care market, includes blood glucose meters, blood glucose test strips, lancets, continuous glucose monitoring (CGM), flash glucose monitoring (FGM), insulin, insulin pens, insulin syringes, and insulin pumps. Previously, the U.S. diabetes monitoring, treatment, and drug-delivery market was valued at $15.7